Trials / Active Not Recruiting
Active Not RecruitingNCT06539195
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Dizal Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DZD8586 | Daily dose of DZD8586 at 25 mg |
| DRUG | DZD8586 | Daily dose of DZD8586 at 50 mg |
| DRUG | DZD8586 | Daily dose of DZD8586 at 75 mg |
Timeline
- Start date
- 2024-03-13
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-08-06
- Last updated
- 2026-03-04
Locations
14 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06539195. Inclusion in this directory is not an endorsement.